Roche Upbeat On Ocrevus Despite Consensus Miss

COVID-19 And Competition Slows Growth

Fewer patients with multiple sclerosis are switching treatment during the pandemic but despite that, and the arrival of competition from Novartis's Kesimpta, Roche insists Ocrevus growth remains strong.

Pathway
Patients unwilling to change treatment pathways in the pandemic • Source: Shutterstock

Although fourth-quarter 2020 sales of Roche Holding AG's multiple sclerosis blockbuster Ocrevus were well down on analyst forecasts, the Swiss major is confident about the drug's long-term prospects and its ability to fend off Novartis AG's newly launched rival Kesimpta.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Neurological

More from Therapy Areas

GSK Chief Optimistic About BD Despite Volatile Environment

 
• By 

Emma Walmsley tells Scrip that the "biotech market is under a certain degree of pressure," so reasonably priced deals are available.

In Brief: AbbVie’s Rinvoq Secures US Approval For Giant Cell Arteritis

 

JAK inhibitor gains ninth indication in US after a strong performance in the first quarter.

CSPC’s Global-First Monospecific ADC Promising In Advanced NSCLC

 
• By 

CSPC’s SYS6010, the first monospecific EGFR-targeting antibody-drug conjugate in the clinic for advanced NSCLC, has shown Phase I promise, but could face close competition with another China-originated bispecific.